GABAB receptor agonist baclofen improves methamphetamine-induced cognitive deficit in mice

Sawako Arai; Kazuhiro Takuma; Hiroyuki Mizoguchi; Daisuke Ibi; Taku Nagai; Hiroyuki Kamei; Hyoung Chun Kim; Kiyofumi Yamada

doi:10.1016/j.ejphar.2008.10.065

GABA_B receptor agonist baclofen improves methamphetamine-induced cognitive deficit in mice

Sawako Arai
, Kazuhiro Takuma
, Hiroyuki Mizoguchi
, Daisuke Ibi
, Taku Nagai
, Hiroyuki Kamei
, Hyoung Chun Kim
, Kiyofumi Yamada

研究成果: ジャーナルへの寄稿 › 学術論文 › 査読

48 被引用数 (Scopus)

抄録

In this study, we investigated the effects of GABA_A and GABA_B receptor agonists on the methamphetamine-induced impairment of recognition memory in mice. Repeated treatment with methamphetamine at a dose of 1 mg/kg for 7 days induced an impairment of recognition memory. Baclofen, a GABA_B receptor agonist, ameliorated the repeated methamphetamine-induced cognitive impairment, although gaboxadol, a GABA_A receptor agonist, had no significant effect. GABA_B receptors may constitute a putative new target in treating cognitive deficits in patients suffering from schizophrenia, as well as methamphetamine psychosis.

本文言語	英語
ページ（範囲）	101-104
ページ数	4
ジャーナル	European Journal of Pharmacology
巻	602
号	1
DOI	https://doi.org/10.1016/j.ejphar.2008.10.065
出版ステータス	出版済み - 05-01-2009
外部発表	はい

All Science Journal Classification (ASJC) codes

薬理学

文献へのアクセス

10.1016/j.ejphar.2008.10.065

他のファイルとリンク

引用スタイル

@article{93b992b76b724c4abef1237a164ef425,

title = "GABAB receptor agonist baclofen improves methamphetamine-induced cognitive deficit in mice",

abstract = "In this study, we investigated the effects of GABAA and GABAB receptor agonists on the methamphetamine-induced impairment of recognition memory in mice. Repeated treatment with methamphetamine at a dose of 1 mg/kg for 7 days induced an impairment of recognition memory. Baclofen, a GABAB receptor agonist, ameliorated the repeated methamphetamine-induced cognitive impairment, although gaboxadol, a GABAA receptor agonist, had no significant effect. GABAB receptors may constitute a putative new target in treating cognitive deficits in patients suffering from schizophrenia, as well as methamphetamine psychosis.",

keywords = "Baclofen, Cognitive deficit, Methamphetamine, Schizophrenia",

author = "Sawako Arai and Kazuhiro Takuma and Hiroyuki Mizoguchi and Daisuke Ibi and Taku Nagai and Hiroyuki Kamei and Kim, \{Hyoung Chun\} and Kiyofumi Yamada",

note = "Funding Information: This study was supported in part by a Grant-in-Aid for Scientific Research (No.19390062) from the Japan Society for the Promotion of Science and grants for the 21st century COE program from the Ministry of Education, Culture, Sports, Science and Technology of Japan, the Smoking Research Foundation, Japan, the JSPS and KOSEF under the Japan–Korea Basic Scientific Cooperation Program, the Academic Frontier Project for Private Universities; matching fund subsidy from MEXT, 2007–2011, and the Research on Risk of Chemical Substances, Health and Labour Science Research Grants supported by Ministry of Health, Labour and Welfare, and JST, CREST.",

year = "2009",

month = jan,

day = "5",

doi = "10.1016/j.ejphar.2008.10.065",

language = "English",

volume = "602",

pages = "101--104",

journal = "European Journal of Pharmacology",

issn = "0014-2999",

publisher = "Elsevier B.V.",

number = "1",

}

TY - JOUR

T1 - GABAB receptor agonist baclofen improves methamphetamine-induced cognitive deficit in mice

AU - Arai, Sawako

AU - Takuma, Kazuhiro

AU - Mizoguchi, Hiroyuki

AU - Ibi, Daisuke

AU - Nagai, Taku

AU - Kamei, Hiroyuki

AU - Kim, Hyoung Chun

AU - Yamada, Kiyofumi

N1 - Funding Information: This study was supported in part by a Grant-in-Aid for Scientific Research (No.19390062) from the Japan Society for the Promotion of Science and grants for the 21st century COE program from the Ministry of Education, Culture, Sports, Science and Technology of Japan, the Smoking Research Foundation, Japan, the JSPS and KOSEF under the Japan–Korea Basic Scientific Cooperation Program, the Academic Frontier Project for Private Universities; matching fund subsidy from MEXT, 2007–2011, and the Research on Risk of Chemical Substances, Health and Labour Science Research Grants supported by Ministry of Health, Labour and Welfare, and JST, CREST.

PY - 2009/1/5

Y1 - 2009/1/5

N2 - In this study, we investigated the effects of GABAA and GABAB receptor agonists on the methamphetamine-induced impairment of recognition memory in mice. Repeated treatment with methamphetamine at a dose of 1 mg/kg for 7 days induced an impairment of recognition memory. Baclofen, a GABAB receptor agonist, ameliorated the repeated methamphetamine-induced cognitive impairment, although gaboxadol, a GABAA receptor agonist, had no significant effect. GABAB receptors may constitute a putative new target in treating cognitive deficits in patients suffering from schizophrenia, as well as methamphetamine psychosis.

AB - In this study, we investigated the effects of GABAA and GABAB receptor agonists on the methamphetamine-induced impairment of recognition memory in mice. Repeated treatment with methamphetamine at a dose of 1 mg/kg for 7 days induced an impairment of recognition memory. Baclofen, a GABAB receptor agonist, ameliorated the repeated methamphetamine-induced cognitive impairment, although gaboxadol, a GABAA receptor agonist, had no significant effect. GABAB receptors may constitute a putative new target in treating cognitive deficits in patients suffering from schizophrenia, as well as methamphetamine psychosis.

KW - Baclofen

KW - Cognitive deficit

KW - Methamphetamine

KW - Schizophrenia

UR - https://www.scopus.com/pages/publications/57249108189

UR - https://www.scopus.com/pages/publications/57249108189#tab=citedBy

U2 - 10.1016/j.ejphar.2008.10.065

DO - 10.1016/j.ejphar.2008.10.065

M3 - Article

C2 - 19028488

AN - SCOPUS:57249108189

SN - 0014-2999

VL - 602

SP - 101

EP - 104

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

IS - 1

ER -